



BNP PARIBAS
ASSET MANAGEMENT

Notice for investors in the AXA Framlington Biotech Fund and the AXA Framlington Health Fund

BNP Paribas Asset Management can confirm that Cinney Zhang, Portfolio Manager, has decided to leave the company to pursue a new opportunity.

Cinney will be leaving during June 2026, and will work closely with the investment team to ensure a smooth transition.

Cinney co-manages the AXA Framlington Biotech Fund and the AXA Framlington Health Fund.

Existing members of the investment team, Chris Eccles and Catherine Tennyson, who are already co-managing these funds, will assume Cinney's responsibilities under the leadership of Tom Riley (Head of Global Thematic Strategies).

AXA IM and BNPP AM are progressively merging and streamlining our legal entities to create a unified structure. AXA Investment Managers joined BNP Paribas Group in July 2025. Following the merger of AXA Investment Managers Paris and BNP Paribas Asset Management Europe and their respective holding companies on December 31, 2025, the combined companies now operate under the **BNP Paribas Asset Management** brand.

Important information

This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.

Before making an investment, investors should read the relevant Prospectus and the Key Investor Information Document / scheme documents, which provide full product details including investment charges and risks. The information contained herein is not a substitute for those documents or for professional external advice. The products or strategies discussed in this document may not be registered nor available in your jurisdiction. Please check the countries of registration with the asset manager, or on the web site <https://www.axaim.com/en/registration-map>, where a fund registration map is available. In particular units of the funds may not be offered, sold or delivered to U.S. Persons within the meaning of Regulation S of the U.S. Securities Act of 1933. The tax treatment relating to the holding, acquisition or disposal of shares or units in the fund depends on each investor's tax status or treatment and may be subject to change. Any potential investor is strongly encouraged to seek advice from its own tax advisers.

For more information on sustainability-related aspects please visit <https://www.axaim.com/what-is-sfdr>

Issued in the UK by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales No: 01431068. Registered Office: 22 Bishopsgate London EC2N 4BQ

In other jurisdictions, this document is issued by AXA Investment Managers SA's affiliates in those countries